The Epidemiology and Pathophysiology of Kidney Disease in HFpEF With Obesity
University of Mississippi Medical Center · NCT07052539
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18–75 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Observational
- Target enrollment
- 60
- US sites recruiting
- 1
- Study start
- July 22, 2022
- Record last updated
- July 4, 2025
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
This research study wants to learn about Chronic Kidney Disease (CKD) with Obesity, and Heart Failure with preserved Ejection Fraction (HFpEF) and better ways to evaluate these diseases. HFpEF means that the heart is not able to fill properly with blood while it is resting so the amount of blood pumped out to the body is less than it would be if it was filling properly. The study is being done to describe the differences in how the kidneys handle protein and salt in participants with HFpEF and obesity compared to healthy persons.
Being studied: High protein and sodium meal
Conditions: Chronic Kidney Disease; Heart Failure With Preserved Ejection Fraction (HFPEF); Obesity (Disorder)
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Criteria for Cohort 1: Healthy Participants
Inclusion Criteria
- Adults 18-75 years old
- Normal kidney function
- No heart failure
- BMI 25-30kg/m2
Exclusion Criteria
- Diagnosis of chronic illness
- eGFR\<60mL/min/1.73m2
- Pregnancy or breast feeding
- History of cutaneous or allergic reaction to iodine-based products of contrast dyes
- Hemoglobin levels \<7mg/dL
- Acute illness or hospitalization event within 3 months
- Unable to stop NSAIDs
- Comorbid conditions: MM, amyloidosis, pheochromocytoma, SCD, metastatic brain lesions, advanced kidney disease, liver dysfunction, endotoxemia, hyperthyroidism
- Current use of nicotine or recreational drugs, chronic drinker
Criteria for Cohort 2: Obese Participants without HFpEF
Inclusion Criteria
- Adults 18-75 years old
- eGFR >= 60 mL/min/1.73m2
- BMI > 35 kg/m2
Exclusion Criteria
- Diagnosis of Heart Failure
- Diagnosis of chronic illness
- eGFR\<60mL/min/1.73m2
- Pregnancy or breast feeding
- History of cutaneous or allergic reaction to iodine-based products of contrast dyes
- Hemoglobin levels \<7mg/dL
- Acute illness or hospitalization event within 3 months
- Unable to stop NSAIDs
- Comorbid conditions: MM, amyloidosis, pheochromocytoma, SCD, metastatic brain lesions, advanced kidney disease, liver dysfunction, endotoxemia, hyperthyroidism
- Current use of nicotine or recreational drugs, chronic drinker
Criteria for Cohort 3: HFpEF and Obese Participants
Inclusion Criteria
- Adults 18-75 years old
- eGFR >= 60 mL/min/1.73m2
- BMI > 35 kg/m2
- Diagnosis of HFpEF (chart diagnosis, LVEF > 55% on echo, H2FPEF score 6-9 or HFA-PEFF score 5 or 6
Exclusion Criteria
- NYHA class III/IV
- Urinary retention screen +
- Mobility issues
- History of RRT or kidney transplant
- Acute illness/hospitalization in the past 3 months
- History of cancer, chemo, or XRT
- Pregnant/breastfeeding
- History of allergies to contrast
- Hemoglobin \< 7
- Comorbid conditions: MM, amyloidosis, pheochromocytoma, SCD, metastatic brain lesions, advanced kidney disease, liver dysfunction, endotoxemia, hyperthyroidism
- Unable to stop NSAIDs
- Current use of nicotine or recreational drugs, chronic drinker
Recruiting US locations
University of Mississippi Medical Center
Jackson, MS 39216
Site contact: Tekka Johnson · 601-496-7834 · tjohnson23@umc.edu
Study contacts (from the official record)
- Tekka Johnson · 601-496-7834 · tjohnson23@umc.edu
Similar studies in Mississippi
All weight loss studies in Mississippi →- RecruitingHealthy volunteersPhase 3
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
- Location
- Gulfport, MS + 55 other US sites
- Eligibility basics
- Ages 18–79
- RecruitingPhase 3
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
Amgen
- Location
- Ridgeland, MS + 51 other US sites
- Eligibility basics
- Ages 18–99
- RecruitingPhase 2
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
AbbVie
- Location
- Fayette, MS + 58 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
Hoffmann-La Roche
- Location
- Gulfport, MS + 43 other US sites
- Eligibility basics
- Ages 18+